fda changes to tirzepatide Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management TrimRX | Semaglutide vs Tirzepatide:

This is the fastest way to get your prescription to the new pharmacy

Your PlexusDx provider can review your complete health history and adjust your treatment plan accordingly

no clear plateau) Zepbound: ~20% to 22.5% (long-term studies) Glycemic Control (T2D): Retatrutide: HbA1c reduction up to ~2.0% (Phase III) Zepbound: Strong, well-established HbA1c reductions (~2.0% to 2.4%) across Phase III trials Durability of Effect: Retatrutide: Sustained weight loss with continued decline over time Zepbound: Durable, but tends to plateau earlier Safety & Tolerability: Retatrutide: Higher rates of GI side effects

Weight loss is a journey that doesnt happen overnight

Payers want BMI history, step therapy evidence where required, and qualifying comorbidities documented in full

This choice ensures consistency in dosing, safety, and efficacy